Non-Hormonal Therapy for Menopausal VMS: How Does Elinzanetant Differ from HRT?

"Felinzanetant and elinzanetant are among the first drugs that are taking advantage of this newly understood neurokinin pathway in the brain that appears to control hot flashes.”

That is what JoAnn Pinkerton, MD, professor of obstetrics and gynecology and division director of Midlife Health at the University of Virginia Health System in Charlottesville, Virginia, said in a recent interview with Patient Care Online. Dr Pinkerton was asked how elinzanetant—a novel selective nonhormonal dual neurokinin-1,3 (NK-1,3) receptor antagonist in late-stage clinical development for moderate-to-severe vasomotor symptoms (VMS)—differs from other currently available medications for VMS, such as hormone replacement therapy and felinzanetant, a non-hormonal therapy that has recently received FDA approval. She explains further in the video above.

Dr Pinkerton is also the national lead for the OASIS clinical trial program examining the efficacy and safety of elinzanetant. Check out part 1 of our video interview series with Dr Pinkerton for study details.